U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C33H38N4O6.ClH.3H2O
Molecular Weight 677.185
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IRINOTECAN HYDROCHLORIDE

SMILES

O.O.O.Cl.CCC1=C2C=C(OC(=O)N3CCC(CC3)N4CCCCC4)C=CC2=NC5=C1CN6C5=CC7=C(COC(=O)[C@]7(O)CC)C6=O

InChI

InChIKey=KLEAIHJJLUAXIQ-JDRGBKBRSA-N
InChI=1S/C33H38N4O6.ClH.3H2O/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2;;;;/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3;1H;3*1H2/t33-;;;;/m0..../s1

HIDE SMILES / InChI
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C33H38N4O6
Molecular Weight 586.678
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. Irinotecan is sold under the brand name Camptosar among others. CAMPTOSAR is a topoisomerase inhibitor indicated for: • First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. • Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I, which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.

CNS Activity

CNS Penetrant
2554
Curator's Comment: Irinotecan crosses the blood-brain barrier

Originator

Approval Year

1996
225
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
CAMPTOSAR

Approved Use

CAMPTOSAR is a topoisomerase inhibitor indicated for: • First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. (1) • Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.

Launch Date

1996
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3392 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020571s051lbl.pdf
340 mg/m² single, intravenous
dose: 340 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IRINOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1660 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020571s051lbl.pdf
125 mg/m² single, intravenous
dose: 125 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IRINOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
20604 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020571s051lbl.pdf
340 mg/m² single, intravenous
dose: 340 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IRINOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
10200 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020571s051lbl.pdf
125 mg/m² single, intravenous
dose: 125 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IRINOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.7 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020571s051lbl.pdf
340 mg/m² single, intravenous
dose: 340 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IRINOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
5.8 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020571s051lbl.pdf
125 mg/m² single, intravenous
dose: 125 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IRINOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
51%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020571s051lbl.pdf
125 mg/m² single, intravenous
dose: 125 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IRINOTECAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
21 mg/m2 1 times / day multiple, oral
MTD
Dose: 21 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 21 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
unhealthy, adult
n = 12
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
Other AEs: Fatigue, Weight loss...
Other AEs:
Fatigue (grade 1-2, 33.3%)
Weight loss (grade 1-2, 33.3%)
Diarrhea (grade 1-2, 50%)
Nausea (grade 1-2, 58.3%)
Vomiting (grade 1-2, 50%)
Cholinergic syndrome (grade 1-2, 33.3%)
Mucositis (grade 1-2, 33.3%)
Dyspnea (grade 1-2, 8.3%)
Fever (grade 1-2, 8.3%)
Fatigue (grade 3, 8.3%)
Diarrhea (grade 3, 8.3%)
Nausea (grade 3, 8.3%)
Vomiting (grade 3, 8.3%)
Cholinergic syndrome (grade 3, 33.3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
290 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 290 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 290 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 7
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Other AEs: Leukopenia, Leukopenia...
Other AEs:
Leukopenia (grade 2, 1 patient)
Leukopenia (grade 3, 2 patients)
Leukopenia (grade 4, 1 patient)
Neutropenia (grade 2, 2 patients)
Neutropenia (grade 3, 2 patients)
Neutropenia (grade 4, 1 patient)
Nausea (grade 1, 4 patients)
Nausea (grade 3, 1 patient)
Vomiting (grade 4, 1 patient)
Diarrhea (grade 1, 2 patients)
Diarrhea (grade 2, 3 patients)
Diarrhea (grade 4, 1 patient)
Anorexia (grade 1, 3 patients)
Anorexia (grade 2, 2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
320 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 320 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 320 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Other AEs: Leukopenia, Leukopenia...
Other AEs:
Leukopenia (grade 1, 4 patients)
Leukopenia (grade 2, 1 patient)
Leukopenia (grade 3, 2 patients)
Neutropenia (grade 1, 2 patients)
Neutropenia (grade 2, 2 patients)
Neutropenia (grade 4, 2 patients)
Thrombocytopenia (grade 1, 2 patients)
Nausea (grade 1, 3 patients)
Nausea (grade 2, 3 patients)
Nausea (grade 3, 2 patients)
Vomiting (grade 1, 2 patients)
Vomiting (grade 2, 2 patients)
Vomiting (grade 3, 1 patient)
Vomiting (grade 4, 1 patient)
Diarrhea (grade 1, 3 patients)
Diarrhea (grade 2, 2 patients)
Diarrhea (grade 3, 1 patient)
Diarrhea (grade 4, 1 patient)
Anorexia (grade 1, 3 patients)
Anorexia (grade 2, 2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
AEs

AEs

AESignificanceDosePopulation
Cholinergic syndrome grade 1-2, 33.3%
21 mg/m2 1 times / day multiple, oral
MTD
Dose: 21 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 21 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
unhealthy, adult
n = 12
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
Fatigue grade 1-2, 33.3%
21 mg/m2 1 times / day multiple, oral
MTD
Dose: 21 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 21 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
unhealthy, adult
n = 12
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
Mucositis grade 1-2, 33.3%
21 mg/m2 1 times / day multiple, oral
MTD
Dose: 21 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 21 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
unhealthy, adult
n = 12
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
Weight loss grade 1-2, 33.3%
21 mg/m2 1 times / day multiple, oral
MTD
Dose: 21 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 21 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
unhealthy, adult
n = 12
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
Diarrhea grade 1-2, 50%
21 mg/m2 1 times / day multiple, oral
MTD
Dose: 21 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 21 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
unhealthy, adult
n = 12
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
Vomiting grade 1-2, 50%
21 mg/m2 1 times / day multiple, oral
MTD
Dose: 21 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 21 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
unhealthy, adult
n = 12
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
Nausea grade 1-2, 58.3%
21 mg/m2 1 times / day multiple, oral
MTD
Dose: 21 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 21 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
unhealthy, adult
n = 12
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
Dyspnea grade 1-2, 8.3%
21 mg/m2 1 times / day multiple, oral
MTD
Dose: 21 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 21 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
unhealthy, adult
n = 12
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
Fever grade 1-2, 8.3%
21 mg/m2 1 times / day multiple, oral
MTD
Dose: 21 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 21 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
unhealthy, adult
n = 12
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
Cholinergic syndrome grade 3, 33.3%
21 mg/m2 1 times / day multiple, oral
MTD
Dose: 21 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 21 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
unhealthy, adult
n = 12
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
Diarrhea grade 3, 8.3%
21 mg/m2 1 times / day multiple, oral
MTD
Dose: 21 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 21 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
unhealthy, adult
n = 12
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
Fatigue grade 3, 8.3%
21 mg/m2 1 times / day multiple, oral
MTD
Dose: 21 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 21 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
unhealthy, adult
n = 12
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
Nausea grade 3, 8.3%
21 mg/m2 1 times / day multiple, oral
MTD
Dose: 21 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 21 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
unhealthy, adult
n = 12
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
Vomiting grade 3, 8.3%
21 mg/m2 1 times / day multiple, oral
MTD
Dose: 21 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 21 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
unhealthy, adult
n = 12
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/30406838/
Diarrhea grade 1, 2 patients
290 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 290 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 290 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 7
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Anorexia grade 1, 3 patients
290 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 290 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 290 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 7
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Nausea grade 1, 4 patients
290 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 290 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 290 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 7
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Leukopenia grade 2, 1 patient
290 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 290 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 290 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 7
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Anorexia grade 2, 2 patients
290 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 290 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 290 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 7
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Neutropenia grade 2, 2 patients
290 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 290 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 290 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 7
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Diarrhea grade 2, 3 patients
290 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 290 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 290 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 7
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Nausea grade 3, 1 patient
290 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 290 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 290 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 7
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Leukopenia grade 3, 2 patients
290 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 290 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 290 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 7
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Neutropenia grade 3, 2 patients
290 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 290 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 290 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 7
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Diarrhea grade 4, 1 patient
290 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 290 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 290 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 7
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Leukopenia grade 4, 1 patient
290 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 290 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 290 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 7
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Neutropenia grade 4, 1 patient
290 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 290 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 290 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 7
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Vomiting grade 4, 1 patient
290 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 290 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 290 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 7
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Neutropenia grade 1, 2 patients
320 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 320 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 320 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Thrombocytopenia grade 1, 2 patients
320 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 320 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 320 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Vomiting grade 1, 2 patients
320 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 320 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 320 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Anorexia grade 1, 3 patients
320 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 320 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 320 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Diarrhea grade 1, 3 patients
320 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 320 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 320 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Nausea grade 1, 3 patients
320 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 320 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 320 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Leukopenia grade 1, 4 patients
320 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 320 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 320 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Leukopenia grade 2, 1 patient
320 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 320 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 320 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Anorexia grade 2, 2 patients
320 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 320 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 320 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Diarrhea grade 2, 2 patients
320 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 320 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 320 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Neutropenia grade 2, 2 patients
320 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 320 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 320 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Vomiting grade 2, 2 patients
320 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 320 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 320 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Nausea grade 2, 3 patients
320 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 320 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 320 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Diarrhea grade 3, 1 patient
320 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 320 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 320 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Vomiting grade 3, 1 patient
320 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 320 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 320 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Leukopenia grade 3, 2 patients
320 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 320 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 320 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Nausea grade 3, 2 patients
320 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 320 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 320 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Diarrhea grade 4, 1 patient
320 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 320 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 320 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Vomiting grade 4, 1 patient
320 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 320 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 320 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Neutropenia grade 4, 2 patients
320 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 320 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 320 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
unhealthy, adult
n = 8
Health Status: unhealthy
Condition: solid tumors
Age Group: adult
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/10873073/
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:80630
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:80630
ChemicalBook
CB1124156
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1124156
MolPort
MolPort-003-848-231
https://www.molport.com/shop/molecule-link/MolPort-003-848-231
Selleck Chemicals
Irinotecan
http://www.selleckchem.com/products/Irinotecan.html
ZINC
ZINC000001612996
http://zinc15.docking.org/substances/ZINC000001612996
eMolecules
31588824
https://www.emolecules.com/cgi-bin/more?vid=31588824
eMolecules
901988
https://www.emolecules.com/cgi-bin/more?vid=901988
PubMed

PubMed

TitleDatePubMed
Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.
2000 Mar 1
Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer.
2001
Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11.
2001
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
2001
[Home chemotherapy and/or outpatient chemotherapy for patient with advanced gastric cancer].
2001 Apr
Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.
2001 Apr
26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.
2001 Apr 2-27
[Medical treatment of pulmonary neoplasms].
2001 Feb
North Central Cancer Treatment Group--Mayo Clinic trials in colon cancer.
2001 Feb
Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study.
2001 Feb 15
Effect of bile acids on the uptake of irinotecan and its active metabolite, SN-38, by intestinal cells.
2001 Feb 16
Irinotecan in small-cell lung cancer: the US experience.
2001 Jan
Oral fluoropyrimidine-based combination therapy in gastrointestinal cancer.
2001 Jan
A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
2001 Jan
Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.
2001 Jan
A phase II study of irinotecan in patients with advanced hepatocellular carcinoma.
2001 Jan 1
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
2001 Jan 15
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
2001 Jan 25
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
2001 Jan 25
New chemotherapy approaches in colorectal cancer.
2001 Jul
Control of irinotecan-induced diarrhea by octreotide after loperamide failure.
2001 Jun
Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.
2001 Jun
Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma.
2001 Mar 16
CPT-11 alters the circadian rhythm of dihydropyrimidine dehydrogenase mRNA in mouse liver.
2001 May
Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients.
2001 May
Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides.
2001 May
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
2001 May 1
Patents

Patents

JP2002527466A
10
JP2006519850A
6
JP2006523680A
10
JP2006528196A
42
JP2007161714A
6
JP2008273952A
8
JP2008519861A
32
JP2009513567A
65
JP2011168619A
8
JP2011510632A
12
JP2011522802A
30
JP2011529474A
10
JP2011529950A
8
JP3775780B2
13
JP4776843B2
17

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Colorectal Cancer Either as a single agent or in combination with fluorouracil and leucovorin: 125 mg/m2 intravenously over 90 minutes once a week for four doses or as a single agent: 350 mg/m2 intravenously over 90 minutes every three weeks or in combination with fluorouracil and leucovorin: 180 mg/m2 intravenously over 90 minutes every other week for three doses.
Route of Administration: Intravenous
In Vitro Use Guide
The sensitivity to CPT-11 (Irinotecan) alone, of 5 human colon-cancer cell lines, expressed as IC50 values, varied between 2.5 and 6.1uM. The anti-proliferative effectsof the active metabolite SN-38 showed IC50 values between 5.6 and 38 nM, 130 to 570 times lower than those measured for CPT-11 alone. The sensitivity to SN-38 was highest in LS174T and COLO320 cells, intermediate in SW1398 cells and lowest in COLO 205 and WiDr cells.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:32:57 GMT 2023
Edited
by admin
on Fri Dec 15 15:32:57 GMT 2023
Record UNII
042LAQ1IIS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IRINOTECAN HYDROCHLORIDE
MART.   ORANGE BOOK   USAN   USP   USP-RS   VANDF  
USAN  
Official Name English
IRINOTECAN HYDROCHLORIDE [MART.]
Common Name English
ONIVYDE
Brand Name English
U-101,440E
Code English
IRINOTECAN HYDROCHLORIDE [ORANGE BOOK]
Common Name English
IRINOTECAN HYDROCHLORIDE TRIHYDRATE [EP MONOGRAPH]
Common Name English
IRINOTECAN HYDROCHLORIDE [USP-RS]
Common Name English
IRINOTECAN HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
IRINOTECAN HYDROCHLORIDE HYDRATE
JAN  
Common Name English
NSC-759878
Code English
XELIRI COMPONENT IRINOTECAN HYDROCHLORIDE
Common Name English
IRINOTECAN HYDROCHLORIDE [USAN]
Common Name English
(1,4'-BIPIPERIDINE)-1'-CARBOXYLIC ACID, 4,11-DIETHYL-3,4,12,14-TETRAHYDRO-4-HYDROXY-3,14-DIOXO-1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLIN-9-YL ESTER, MONOHYDROCHLORIDE, TRIHYDRATE, (S)-
Common Name English
CPT-11
Code English
CAMPTO
Brand Name English
IRINOTECAN HYDROCHLORIDE TRIHYDRATE
MI  
Common Name English
(+)-7-ETHYL-10-HYDROXYCAMPTOTHECINE 10-(1,4'-BIPIPERIDINE)-1'-CARBOXYLATE, MONOHYDROCHLORIDE, TRIHYDRATE
Common Name English
IRINOTECAN HYDROCHLORIDE TRIHYDRATE [EMA EPAR]
Common Name English
DQ-2805
Code English
IRINOTECAN HYDROCHLORIDE TRIHYDRATE [MI]
Common Name English
IRINOTECAN HYDROCHLORIDE HYDRATE [JAN]
Common Name English
CAMPTOSAR
Brand Name English
Irinotecan hydrochloride trihydrate [WHO-DD]
Common Name English
IRINOTECAN HYDROCHLORIDE [VANDF]
Common Name English
IRINOTECAN MONOHYDROCHLORIDE TRIHYDRATE
WHO-DD  
Common Name English
U-101440E
Code English
Classification Tree Code System Code
EU-Orphan Drug EU/3/11/933
Created by admin on Fri Dec 15 15:32:57 GMT 2023 , Edited by admin on Fri Dec 15 15:32:57 GMT 2023
EMA ASSESSMENT REPORTS ONIVYDE (AUTHORIZED: PANCREATIC NEOPLASMS):
Created by admin on Fri Dec 15 15:32:57 GMT 2023 , Edited by admin on Fri Dec 15 15:32:57 GMT 2023
NCI_THESAURUS C2843
Created by admin on Fri Dec 15 15:32:57 GMT 2023 , Edited by admin on Fri Dec 15 15:32:57 GMT 2023
Code System Code Type Description
USAN
HH-3
Created by admin on Fri Dec 15 15:32:57 GMT 2023 , Edited by admin on Fri Dec 15 15:32:57 GMT 2023
PRIMARY
PUBCHEM
60837
Created by admin on Fri Dec 15 15:32:57 GMT 2023 , Edited by admin on Fri Dec 15 15:32:57 GMT 2023
PRIMARY
EPA CompTox
DTXSID60929485
Created by admin on Fri Dec 15 15:32:57 GMT 2023 , Edited by admin on Fri Dec 15 15:32:57 GMT 2023
PRIMARY
NSC
759878
Created by admin on Fri Dec 15 15:32:57 GMT 2023 , Edited by admin on Fri Dec 15 15:32:57 GMT 2023
PRIMARY
DAILYMED
042LAQ1IIS
Created by admin on Fri Dec 15 15:32:57 GMT 2023 , Edited by admin on Fri Dec 15 15:32:57 GMT 2023
PRIMARY
EVMPD
SUB02772MIG
Created by admin on Fri Dec 15 15:32:57 GMT 2023 , Edited by admin on Fri Dec 15 15:32:57 GMT 2023
PRIMARY
RXCUI
153329
Created by admin on Fri Dec 15 15:32:57 GMT 2023 , Edited by admin on Fri Dec 15 15:32:57 GMT 2023
PRIMARY RxNorm
EVMPD
SUB45873
Created by admin on Fri Dec 15 15:32:57 GMT 2023 , Edited by admin on Fri Dec 15 15:32:57 GMT 2023
PRIMARY
FDA UNII
042LAQ1IIS
Created by admin on Fri Dec 15 15:32:57 GMT 2023 , Edited by admin on Fri Dec 15 15:32:57 GMT 2023
PRIMARY
CHEBI
90881
Created by admin on Fri Dec 15 15:32:57 GMT 2023 , Edited by admin on Fri Dec 15 15:32:57 GMT 2023
PRIMARY
NCI_THESAURUS
C1381
Created by admin on Fri Dec 15 15:32:57 GMT 2023 , Edited by admin on Fri Dec 15 15:32:57 GMT 2023
PRIMARY
CAS
136572-09-3
Created by admin on Fri Dec 15 15:32:57 GMT 2023 , Edited by admin on Fri Dec 15 15:32:57 GMT 2023
PRIMARY
SMS_ID
100000131566
Created by admin on Fri Dec 15 15:32:57 GMT 2023 , Edited by admin on Fri Dec 15 15:32:57 GMT 2023
PRIMARY
RS_ITEM_NUM
1347609
Created by admin on Fri Dec 15 15:32:57 GMT 2023 , Edited by admin on Fri Dec 15 15:32:57 GMT 2023
PRIMARY
ChEMBL
CHEMBL481
Created by admin on Fri Dec 15 15:32:57 GMT 2023 , Edited by admin on Fri Dec 15 15:32:57 GMT 2023
PRIMARY
MERCK INDEX
m6405
Created by admin on Fri Dec 15 15:32:57 GMT 2023 , Edited by admin on Fri Dec 15 15:32:57 GMT 2023
PRIMARY Merck Index
DRUG BANK
DBSALT000103
Created by admin on Fri Dec 15 15:32:57 GMT 2023 , Edited by admin on Fri Dec 15 15:32:57 GMT 2023
PRIMARY
CHEBI
5971
Created by admin on Fri Dec 15 15:32:57 GMT 2023 , Edited by admin on Fri Dec 15 15:32:57 GMT 2023
PRIMARY
Related Record Type Details
Structure of IRINOTECAN HYDROCHLORIDE ANHYDROUS
ANHYDROUS->SOLVATE
Structure of IRINOTECAN
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of 11-ETHYL IRINOTECAN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of CAMPTOTHECIN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 7,11-DIETHYL-10-HYDROXY CAMPTOTHECIN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 7-ETHYL-10-HYDROXYCAMPTOTHECIN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 10-HYDROXYCAMPTOTHECIN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 7-ETHYLCAMPTOTHECIN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 7-DESETHYL IRINOTECAN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of IRINOTECAN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966